Evidence

Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer

December 1, 2013

PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773–3779 AUTHORS: V.P. Retèl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were €26,786 for the 70-gene and €29,187 for AO. The quality adjusted life years yielded 12.49 and 11.88,…

Read more

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

June 18, 2013

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retèl et al_2013_BMC Cancer_Association Between Genomic Recurrence Risk…  

Read more

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

January 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retèl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Treat_Retel et al_The 21-gene has the highest probability…

Read more

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

May 2, 2010

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen showed the highest survival rates compared to the…

Read more

Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

January 24, 2009

PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: 10.1017/S0266462309090102. AUTHORS: Retèl V.P., Bueno-de-Mesquita J.M., Hummel M.J., van de Vijver M.J., Douma K.F., Karsenberg K., van Dam F.S., van Krimpen C., Bellot F.E., Roumen R.M., Linn S.C., van Harten W.H. SUMMARY: Differences in speed of implementation and influenced treatment decisions were seen. Impact on patients seems especially…

Read more